The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Protein Phosphatase 2A and Regulatory T Cell Function Researched

Protein Phosphatase 2A and Regulatory T Cell Function Researched

June 13, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Antibody-producing cell. B-lymphocyte or T-lymphocyte in blood with red blood cells.

Antibody-producing cell. B-lymphocyte or T-lymphocyte in blood with red blood cells.
Kateryna Kon/shutterstock.com

The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology.

You Might Also Like
  • Adalimumab Drives Regulatory T Cell Expansion by Binding to Membrane TNF
  • 2014 ACR/ARHP Annual Meeting: Regulatory T Cells
  • Treg Cells May Orchestrate Muscle Repair after Injury
Explore This Issue
June 2016
Also By This Author
  • Social & Psychological Elements Are Vital to Rheumatology Care

Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed a severe lymphoproliferative disorder affecting just about every organ. The findings—the latest layers of the onion peeled away in the lab of George Tsokos, MD, chief of the Rheumatology Division at Beth Israel Deaconess Medical Center, Boston—offer a potential new target for the treatment of systemic lupus erythematosus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Tsokos says the findings bring critical new insight into how regulatory T cells do the job of regulating the immune system.1

“In this paper, we saw that it is one enzyme, one phosphatase, that is absolutely needed for the regulatory T cell to be functional,” he says. “And we understand the molecular underpinning for the good function of regulatory T cells.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

PP2A is known to regulate key cellular processes, such as cell-cycle progression, apoptosis, cellular metabolism and migration, and is involved in the development of cancer and neurodegenerative diseases, as well as SLE.

The new understanding about the enzyme is another piece of the puzzle in the complex pathogenesis of SLE, Dr. Tsokos says. Genome-wide association studies have identified genetic susceptibility to the disease and identified more and more people in whom a deficiency in a single gene is responsible for expression of SLE. Smoking, sun exposure and other environmental factors have an epigenetic influence. Hormones clearly play a role, as well, he adds—nine out of 10 people with SLE are women—although the role of hormones is not very well understood.

And then there is abnormal immune regulation.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“All these factors contribute to the expression of the disease, and I would say they act either serially or all together, and in each patient, these factors contribute differentially,” Dr. Tsokos said. “One patient may have more genetic, another patient more epigenetic and so on and so on. … All of these factors acting together generate what I call ‘common effectors of the immune response’: autoantibodies, immune complexes, autoreactive T cells and pro-inflammatory cytokines.” Additionally, he says, organ-specific factors determine which organ will be subject to inflammation and damage.

Long-Term Research

Researchers in Dr. Tsokos’ lab are interested in identifying molecular abnormalities in the immune system and in the organs and then trying to specifically target them. They have been studying T cells in SLE for more than three decades.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: function, Immune, Lupus, lymphoproliferative disorder, neurodegenerative, Protein Phosphatase, regulatory T cell, Research, Rheumatic Disease, rheumatology, SLE, studyIssue: June 2016

You Might Also Like:
  • Adalimumab Drives Regulatory T Cell Expansion by Binding to Membrane TNF
  • 2014 ACR/ARHP Annual Meeting: Regulatory T Cells
  • Treg Cells May Orchestrate Muscle Repair after Injury
  • Patients with Lupus: Plasmacytoid Dendritic Cells Fail to Induce Regulatory B Cells

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.